Long-acting insulins for the management of type 2 diabetes
|
|
- Octavia Wilkinson
- 5 years ago
- Views:
Transcription
1 In Control Long-acting insulins for the management of type 2 diabetes Faculty/presenter disclosure Presenter: Robert Schlosser Relationships with financial sponsors: Grants/Research Support: None Speakers Bureau/Honoraria: Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Janssen, Merck, Boehringer Ingelheim, Amgen, FMF-CFPC Consulting Fees: Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Janssen Patents: None Other: Clinical Studies: Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Janssen 1
2 Disclosure of financial support This program has received financial support from Novo Nordisk Canada Inc. in the form of educational funding This program has received in-kind support from Novo Nordisk Canada Inc. in the form of logistical support Potential for conflict(s) of interest: Dr. Robert Schlosser has received payment/funding, from Novo Nordisk Canada Inc. AND organization whose product(s) are being discussed in this program Novo Nordisk Canada Inc. developed products that will be discussed in this program Mitigating potential bias Bias in this program has been mitigated using independent content validation as follows: All content has been reviewed by a physician steering committee, pharmacist expert reviewers, the College of Family Physicians of Canada, the FMOQ (Fédération des médecins omnipraticiens du Québec), the Canadian Council on Continuing Education in Pharmacy (CCCEP) and the Ordre du Pharmaciens Québec (OPQ) All data have been sourced from clinically accepted evidence All support used in justification of patient care recommendations conforms to generally accepted standards, the Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada, as well as the most recently available clinical data Dr. Robert Schlosser will receive an honorarium from the College of Family Physicians of Canada (CFPC) for this talk 2
3 Planning committee Robert Schlosser, MD, FRCPC Endocrinologist, LMC Diabetes & Endocrinology, Thornhill, ON Medical Director, Mackenzie Health Hospital Diabetes Education Centre Milan Gupta, MD, FRCPC, FACC Associate Clinical Professor of Medicine, McMaster University; Medical Director, Canadian Collaborative Research Network Pierre Filteau, MD, CCFP Family Physician, Centre médical des Carrières (GMF, groupe de médecine familiale), Saint-Marc-des-Carrières, QC Vance Pegado, MD, CCFP Family Physician, Caroline Family Health Team, Burlington, ON Kevin Saunders, MD, CCFP Family Physician, Rivergrove Medical Clinic, Winnipeg, MB Susie Jin, RPh, CDE, CPT, BCGP Community Pharmacist, Pharmacy 101, Cobourg, ON Robert Roscoe, B.Sc.Pharm, ACPR, CDE, CPT Collaborative Community Pharmacist, Consultant, Rothesay, NB Program objectives After attending this program, participants will be able to: Establish the role of basal insulin therapy in the management of type 2 diabetes mellitus (T2DM) as per the 2018 Diabetes Canada clinical practice guidelines Apply strategies to overcome common challenges associated with insulin initiation and optimization and employ knowledge of key concepts, including glucose variability, hypoglycemia and continuous glucose monitoring Compare agent-specific characteristics of the available basal insulins, with a focus on newer basal insulins 3
4 Basal Insulin Initiation Patient Case: Patrick Meet Patrick Health Status BMI: 26.7 kg/m 2 BP: 132/88 mmhg egfr: 78 ml/min/1.73m 2 ACR: Negative LDL: 1.5 mmol/l CV: No history of cardiovascular disease Exercise: Walks briskly 3 times/week for 20 minutes Diet: Eats a balanced diet when at home and has 2 alcoholic drinks, 3 days/week PATRICK 59-year-old male Flight attendant Type 2 diabetes Diagnosed 6 years ago Private insurance coverage Glycemic Parameters A1C: 8.5% FPG: 11.8 mmol/l What glycemic targets would you set for this patient? Medications Gliclazide modified release (90 mg QD) Sitagliptin and metformin HCL-extended release (100 mg sitagliptin/2000 mg metformin QD) Rosuvastatin (10 mg QD) Ramipril (10 mg QD) 4
5 Basal Insulin Initiation Part 1: The relationship between insulin and type 2 diabetes 2018 Diabetes Canada recommendations for pharmacotherapy in type 2 diabetes If metformin and healthy behaviour changes are not enough to control blood glucose, other antihyperglycemic agent (AHA) options can be added Next-line treatment for patients not reaching target: With CV disease Without CV disease On non-insulin AHAs On insulin Add: AHA with CV benefit Options: empagliflozin, liraglutide or canagliflozin* Add: Incretin agent and/or SGLT2i if lower risk of hypoglycemia and/or weight gain are priorities Options: GLP-1 RA or DPP-4i and/or an SGLT2i Add: once-daily basal insulin over premixed or bolus insulin if lower risk of hypoglycemia and/or weight gain are priorities Options: NPH insulin, insulin degludec, insulin detemir or insulin glargine Add: GLP-1 RA, DPP-4i or SGLT2i before adding or intensifying prandial insulin therapy *Avoid in people with prior lower extremity amputation CV, cardiovascular; RA, receptor agonist; DPP-4i, DPP-4 inhibitor; SGLT2i, SLGT2 inhibitor Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325. 5
6 The need for basal insulin in T2DM therapy PAUSE AND REFLECT In general, for patients with T2DM, when do you choose to initiate basal insulin and why? Spotlight on Patrick Patrick has an FPG of >11 mmol/l despite being on oral glucose-lowering agents. How does this impact your next choice of treatment? Basal insulin is initiated later than the Guidelines recommend In a cohort of patients with T2DM treated with insulin by family physicians in Ontario: 9 years average delay to insulin initiation 9.5% mean A1C prior to insulin initiation 74% prevalence of diabetes-related complications prior to insulin initiation PAUSE AND REFLECT Why is basal insulin not being initiated? Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Canadian Family Physician. 2010;56(12):e418-e24. 6
7 Patients may resist starting insulin therapy for various reasons Spotlight on Patrick PAUSE AND REFLECT What are the potential reasons Patrick has been so resistant to starting insulin therapy? Patrick has concerns about insulin and has been putting off starting injectable therapy for over one year I don t think my diabetes is that bad yet. I've been making lifestyle changes to improve my health. Basal Insulin Initiation Part 2: Basal Insulin Options 7
8 Basal insulins currently available in Canada Insulin type Insulin degludec Insulin detemir Insulin glargine NPH Brand name Tresiba 100 units/ml Tresiba 200 units/ml Levemir 100 units/ml Lantus 100 units/ml Basaglar 100 units/ml Toujeo 300 units/ml Novolin ge NPH 100 units/ml Humulin N 100 units/ml Total units per pen (units) Maximum single dose for injection (units) In-use time (days) Pre-filled pen FlexTouch FlexTouch FlexTouch * SoloSTAR * Kwikpen * SoloSTAR Cartridge only Kwikpen * *Also available in cartridges for use in durable/refillable pens; max dose in durable pen may differ from max dose in prefilled pens above Novo Nordisk Canada Inc. Novolin ge Product Monograph ; Eli Lilly Canada Inc. Humulin N Product Monograph. 2016; Novo Nordisk Canada Inc. Levemir Product Monograph ; Sanofi-aventis Canada Inc. Lantus Product Monograph. 2017; Eli Lilly Canada Inc. BASAGLAR TM Product Monograph. 2015; Sanofi-aventis Canada Inc. Toujeo TM Product Monograph. 2015; Novo Nordisk Canada Inc. Tresiba Product Monograph Basal insulin analogues vary in pharmacologic characteristics λ Half life (hours) Duration of action (hours) NPH 5 10 Up to 18 Insulin detemir 5 7 (dose dependent) Insulin glargine U100 U >30 Insulin degludec Up to Novo Nordisk Canada Inc. Novolin ge Product Monograph. 2016; Sanofi-aventis Canada Inc. Lantus Product Monograph. 2017; Sanofi-aventis Canada Inc. Toujeo TM Product Monograph. 2015; Novo Nordisk Canada Inc. Tresiba Product Monograph. 2017; Novo Nordisk Canada Inc. Levemir Product Monograph. 2016; Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1- S325. 8
9 Clinical factors for assessing antidiabetic therapy Effective glycemic control (A1C and FPG lowering) Reminder: no insulin dose ceiling Minimizing risk of hypoglycemia Key factors for Patrick Minimizing weight gain IN YOUR PRACTICE Cardiovascular safety In addition to the clinical factors above, patient characteristics and considerations should impact your decision-making process when individualizing treatment with basal insulin Learn more i Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325. What does Diabetes Canada recommend for basal insulin selection? All basal insulins have essentially the same A1C lowering ability In T2DM, if lower risk of hypoglycemia is a priority: a. Long-acting insulin analogues should be considered over NPH insulin i Learn more b. Insulin degludec may be considered over insulin glargine U100 to reduce overall and nocturnal hypoglycemia, and severe hypoglycemia in patients at high CV risk i Learn more c. Insulin glargine U300 may be considered over insulin glargine U100 to reduce overall and nocturnal hypoglycemia i i Learn more T2DM, type 2 diabetes mellitus Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325. 9
10 PAUSE AND REFLECT Diabetes Canada recommends long-acting basal insulins to reduce the risk of hypoglycemia Insulin degludec and insulin glargine U300 are the basal insulins most recently approved in Canada Both products demonstrated non-inferior A1C reduction when compared head-tohead with insulin glargine U100 with a higher dose of insulin glargine U300 required Insulin degludec demonstrated statistically significant reductions in the rates of nocturnal hypoglycemia and a reduction in the rates of overall hypoglycemia relative to insulin glargine U100 Insulin glargine U300 demonstrated reductions in the number of patients reporting nocturnal confirmed or severe hypoglycemia and confirmed or severe hypoglycemia compared to insulin glargine U100 over the maintenance period. Reductions were significant for nocturnal confirmed or severe hypoglycemia over the entire treatment period. Basal Insulin Initiation Part 3: Initiating Basal Insulin 10
11 Initiating Basal Insulin Checklist Spotlight on Patrick 1. Explain why insulin is needed and describe A1C and FPG targets 2. Demonstrate the pen and titration What is your next treatment approach, in addition to reinforcing and encouraging his healthy behaviour interventions? What factors are important to consider? 3. Teach the patient about self-monitoring blood glucose 4. Set expectations about hypoglycemia and other potential side effects 5. Book a follow-up appointment Canadian Diabetes Association. Insulin pen start checklist. Available at: Retrieved May 1, Explain why insulin is needed and describe A1C and FPG targets IN YOUR PRACTICE Declining pancreatic beta-cell insulin production is part of the natural history of T2DM. Therefore, insulin replacement is often necessary Spotlight on Patrick Patrick feels like he is failing on treatment and is resistant to new medications. How would you address his concerns? OF NOTE Insulin can help achieve glycemic control and prevent long-term complications. Ensure you discuss any changes to his other medications Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S
12 1. Explain why insulin is needed and describe A1C and FPG targets Recommended targets for most patients with T2DM A1C 7.0% FPG mmol/l 2-hr PPG mmol/l If A1C target not achieved: lower FPG target to mmol/l and/or 2-hr PPG target to mmol/l (must be balanced against risk of hypoglycemia) OF NOTE Consider glucose variability reduction as a glycemic target to reduce the risk of vascular diabetes complications i Learn more Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S Demonstrate the pen and titration IN YOUR PRACTICE Consider booking appointments exclusively for insulin initiation and training How will you guide patients in terms of administration and titration? What considerations do you have? Recommendation for T2DM Start: 10 Units once daily Titration: 1 Unit per day until target reached (detemir, glargine and NPH) Degludec should be titrated by 2 Units every 3 4 days or by 4 Units once a week Use the FIT Recommendations at fit4diabetes.com to teach your patients the appropriate injection technique Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325; FIT Forum for Injection Technique Canada. Recommendations for Best Practice in Injection Technique 3rd Edition Available at: Retrieved May 1,
13 3. Teach the patient about self-monitoring blood glucose Recommendation for T2DM Basal insulin + AHAs SMBG at least once a day at variable times T1DM & T2DM: FGM to reduce time in hypoglycemia T1DM and not at target: CGM to improve glycemic control and reduce time in hypoglycemia T2DM, type 2 diabetes mellitus; AHA, antihyperglycemic agent; SMBG, self-monitoring of blood glucose; T1DM, type 1 diabetes mellitus; CGM, continuous glucose monitoring; FGM, flash glucose monitoring Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S Set expectations about hypoglycemia and other potential side effects IN YOUR PRACTICE Discuss hypoglycemia with your patients at every visit. Patients using insulin therapy should be counselled about the risk, prevention, recognition and treatment of hypoglycemia Mild hypoglycemia: Autonomic symptoms Autonomic Neuroglycopenic Moderate: Autonomic and neuroglycopenic symptoms Severe: Unable to self-treat Trembling Palpitations Sweating Anxiety Hunger Nausea Tingling Difficulty concentrating Confusion, weakness, drowsiness, vision changes Difficulty speaking, headache, dizziness Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325; McAulay V, et al. Symptoms of hypoglycaemia in people with diabetes. Diabetic Med. 2001;18(9): ; Canadian Diabetes Association. Lows and highs: blood glucose levels Available at: 13
14 4. Set expectations about hypoglycemia and other potential side effects Recommendation for the treatment of hypoglycemia Test blood glucose Eat 15 g of fast-acting carbohydrate Wait 15 minutes Test again and repeat if necessary If next meal >1 hr away, eat another 15 g carbohydrate and 1 ounce protein Wait 40 minutes before driving Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325. Symptomatic hypoglycemia treatment algorithm Predictable factors? (e.g., food, exercise, alcohol) Nonadherence/ cognitive issues? Secondary cause? (e.g., weight loss, liver/renal failure) Pattern of hypoglycemia? Post-prandial pattern Educate Provide psychosocial support Decrease dose bolus dose Change bolus type Review dose timing Review injection sites Review OADs Fasting/nocturnal/ pre-prandial pattern basal dose Change basal type Review dose timing Review injection sites OAD, oral anti-diabetic drug Blumer I and Clement M. Clin Ther. 2017;39(8S2):S1 S11; Seaquist ER, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab. 2013;98(5):
15 5. Book a follow-up appointment IN YOUR PRACTICE When following up with patients, consider discussing the following topics to enhance your conversations: A1C FPG Current glycemic control Administration, timing and injection site rotation Assessing for low blood sugar* and variability Optimizing control See your handout for potential questions to ask patients at follow-ups and relevant patient considerations *Consider reducing or eliminating insulin secretagogues Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325. Following up with Patrick PATRICK 59-year-old male Flight attendant Type 2 diabetes Diagnosed 6 years ago Private insurance coverage Health Status BMI: 26.7 kg/m 2 BP: 132/88 mmhg egfr: 78 ml/min/1.73m 2 ACR: Negative LDL: 1.5 mmol/l CV: No history of cardiovascular disease Exercise: Walks briskly 3 times/week for 20 minutes Diet: Eats a balanced diet when at home and has 2 alcoholic drinks, 3 days/week Glycemic Parameters A1C: 8.5% (A1C not measured at follow-up) FPG: 8.8 mmol/l Medications Gliclazide modified release (90 mg QD) Sitagliptin and metformin HCL-extended release (100 mg sitagliptin/2000 mg metformin QD) Rosuvastatin (10 mg QD) Ramipril (10 mg QD) Basal insulin 20 units PAUSE AND REFLECT What are you following up on at 1 month keeping in mind the enhancing conversations topics? What if Patrick returned to your practice after 6 months, his FPG was at target, he rarely experienced hypoglycemia, but his A1C was still high? What if his FPG was at target, but he was experiencing daytime hypoglycemia? 15
16 Basal Insulin Optimization Patient Case #2: Priyanka Meet Priyanka Health Status BMI: 29.4 kg/m 2 BP: 138/88 mmhg egfr: 68 ml/min/1.73m 2 ACR: Negative LDL: 1.9 mmol/l CV: No history of cardiovascular disease but strong family history Exercise: On her feet during the day at work Diet: Indian vegetarian diet; does not drink alcohol PRIYANKA 45-year-old female Office administrator Type 2 diabetes Diagnosed 10 years ago Private insurance coverage Insulin Treatment Regimen Basal: Insulin glargine U units at bedtime Glycemic Parameters A1C: 8.3% FPG: 8.5 mmol/l Medications Metformin 1000 mg BID Sitagliptin 100 mg QD Empagliflozin 10 mg QD Atorvastatin 10 mg QD Amlodipine 5 mg QD Was previously on gliclazide but stopped due to daytime hypoglycemia 16
17 Key findings during conversation with Priyanka A1C FPG Current glycemic control Priyanka is frustrated. Her morning FPG ranges greatly, from mmol/l Administration, timing and injection site rotation Very adherent to her treatment regimen and rotates injection sites appropriately Assessing for low blood sugar and variability Sometimes she s dizzy and grumpy during the day, but attributes this to tiredness or hunger Optimizing control Has not been titrating since her last appointment What glycemic targets would you set for Priyanka? She sleeps solidly through the night, but will occasionally have a headache in the morning Sometimes skips breakfast and/or lunch due to hectic work schedule Age: 45 A1C: 8.3% BMI: 29.4 kg/m 2 AHA medications: Metformin, sitagliptin, empagliflozin, atorvastatin and amlodipine Complications: None Basal Insulin Optimization Part 4: Hypoglycemia and its impact 17
18 The real-world impact of hypoglycemia on patients Fear of travelling, leaving home and being alone. ~Dr. Milan Gupta I don't want anyone around me to know I have diabetes. Why on earth would I risk a low? ~Patient of Dr. Vance Pegado During a return demonstration of a blood glucose meter, a patient s random blood glucose was 2.6 mmol/l. Her demeanor was that of shame. It seemed that she was concerned that I was thinking she couldn t care for herself or that she was irresponsible. I actually couldn t let her drive home from the appointment and alternate transportation was arranged. Hesitancy to titrate or increase their therapy/dose. ~Robert Roscoe ~Susie Jin Hypoglycemia is the most common adverse event of insulin therapy, regardless of A1C Canadian perspective 2/3 of patients with T2DM on basal insulin experience hypoglycemia 85% of patients who have experienced a low do not speak to their physicians about hypoglycemia OF NOTE Glucose variability may be a barrier to the optimization of glycemic control due to its association with hypoglycemia Leiter LA, Yale J, Chiasson J, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29(3):186-92, Kovatchev B, et al. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care. 2016;39(4):
19 Glycemic variability can manifest as both within-day variability Glucose (mmol/l) SMBG measurement Hyperglycemia Hypoglycemia Time (hours) SMBG, self-measured blood glucose Adapted from Penckofer, S et al. Diab Tech Ther 2012;14: and day-to-day variability Day 1 Day 3 Glucose (mmol/l) Day 2 Day Time (hours) Adapted from Penckofer S, et al. Diab Tech Ther 2012;14:
20 FPG variability plays a role in hypoglycemia risk FPG (mmol/l) 12.0 Average FPG Target zone Hypoglycemia zone Day FPG (mg/dl) FPG, fasting plasma glucose Adapted from Vora J and Heise T. Diabetes Obes Metab. 2013;15: Lower FPG variability may reduce the risk of hypoglycemia FPG (mmol/l) Average FPG Target zone Hypoglycemia zone FPG, fasting plasma glucose Adapted from Vora J and Heise T. Diabetes Obes Metab. 2013;15: Day Spotlight on Priyanka FPG (mg/dl) You suspect that Priyanka is experiencing nocturnal and daytime hypoglycemia unawareness. How would you confirm this? 20
21 Key features of continuous and flash glucose monitoring CGM FGM Instantaneous realtime display of glucose levels and rate of change of glucose Alerts for impending hyper- and hypoglycemia Ability to characterize glycemic variability Produces an ambulatory glucose profile IN YOUR PRACTICE Real-time CGM has been shown to reduce A1C and reduce time spent in hypoglycemia in adults with T2DM The use of FGM versus SMBG resulted in a similar drop in A1C but a significant reduction in time spent in hypoglycemia, reduced glycemic variability and improved quality of life in individuals with T2DM CGM, continuous glucose monitoring; FGM, flash glucose monitoring Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(S2):S2-3-S2-13; Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325; Ish-Shalom M, Wainstein J, Raz I, Mosenzon O. Improvement in Glucose Control in Difficult-to-Control Patients With Diabetes Using a Novel Flash Glucose Monitoring Device. J Diabetes Sci Technol. 2016;10(6): Basal Insulin Optimization Part 5: Approach to switching to newer basal insulins 21
22 What does Diabetes Canada recommend for basal insulin selection? In T2DM, if lower risk of hypoglycemia is a priority: a. Long-acting insulin analogues should be considered over NPH insulin b. Insulin degludec may be considered over insulin glargine U100 to reduce overall and nocturnal hypoglycemia, and severe hypoglycemia in patients at high CV risk i Learn more c. Insulin glargine U300 may be considered over insulin glargine U100 to reduce overall and nocturnal hypoglycemia i Learn more T2DM, type 2 diabetes mellitus Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325. PAUSE AND REFLECT Insulin degludec and insulin glargine U300 demonstrated non-inferior A1C reductions when compared head-to-head with insulin glargine U100 Insulin degludec demonstrated statistically significant reductions in the rates of overall and nocturnal hypoglycemia and a reduction in the rates of severe hypoglycemia relative to insulin glargine U100 In a randomized, double-blind CVOT, insulin degludec demonstrated statistically significant reductions in the rates of severe and nocturnal severe hypoglycemia relative to insulin glargine U100 Insulin glargine U300 demonstrated a statistically significant reduction in the number of patients reporting nocturnal confirmed or severe hypoglycemia and a reduction in confirmed or severe hypoglycemia compared to insulin glargine U100 Significant reductions in glucose variability demonstrated with insulin degludec compared to insulin glargine U100 and U300 (clamp study results) Low glucose variability is associated with a lower rate of severe hypoglycemia, MACE and all-cause mortality compared to medium or high variability. This rate was not significant for MACE after adjustment. CVOT, cardiovascular outcomes trial; MACE, major adverse cardiovascular events 22
23 Key findings during conversation with Priyanka A1C FPG What if Priyanka was using CGM? Current glycemic control Highly variable day-to-day fasting glucose values and high within-day variability Assessing for low blood sugar and variability Priyanka experiences nocturnal hypo, 2.9 mmol/l, at least 2x a week Still doesn t recognize nocturnal hypo symptoms. However, now that she checks her CGM throughout the day, we know she is not experiencing daytime hypo on a regular basis CGM, continuous glucose monitoring PAUSE AND REFLECT You now know that Priyanka is experiencing nocturnal hypoglycemia unawareness. What are your next steps? What considerations do you have for this patient? Review: How to switch to once-daily basal insulins in T2DM From once-daily From BID From IGlar basal 1,2,3,4 basal 1,2,3,4 U300 1,2 1:1 20% 20% Followed by daily or weekly titration (depending on insulin) 1. Sanofi-aventis Canada Inc. Lantus Product Monograph. 2017; 2. Eli Lilly Canada Inc. BASAGLAR TM Product Monograph. 2015; 3. Sanofi-aventis Canada Inc. Toujeo TM Product Monograph. 2015; 4. Novo Nordisk A/S. Tresiba Summary of Product Characteristics (SmPC). Bagsværd, Denmark
24 In Summary IN YOUR PRACTICE Goal of insulin treatment: Get to A1C target with as few adverse events as possible Enhance conversations with your patients Consider CGM and FGM to reduce A1C and hypoglycemia Nocturnal and symptomatic hypoglycemia: Use basal insulin analogues over NPH Overall and nocturnal hypoglycemia: Use insulin glargine U300 or insulin degludec over insulin glargine U100 Patients at high CV risk: Use insulin degludec over insulin glargine U100 to reduce risk of hypoglycemia Low glucose variability is associated with a lower rate of severe hypoglycemia, MACE and all-cause mortality compared to medium or high variability Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S325. Overview of your participant handout Key takeaways from the 2018 Clinical Practice Guidelines Summary table of insulin options and starting and switching algorithm(s) Enhancing Conversations Guide A1C FPG Current glycemic control Administration, timing and injection site rotation Assessing for low blood sugar and variability Optimizing control 24
25 THANK YOU! 25
26 In Control Long-acting insulins for the management of type 2 diabetes Participant Handout This program has received an educational grant and in-kind support from Novo Nordisk Canada Inc.
27 Patient Cases Patrick 59-year-old male Flight attendant Type 2 diabetes Diagnosed 6 years ago Private insurance coverage Priyanka 45-year-old female Office administrator Type 2 diabetes Diagnosed 10 years ago Private insurance coverage Health Status BMI: 26.7 kg/m 2 BP: 132/88 mmhg egfr: 78 ml/min/1.73m 2 ACR: Negative LDL: 1.5 mmol/l CV: No history of cardiovascular disease Exercise: Walks briskly 3 times/week for 20 minutes Diet: Eats a balanced diet when at home and has 2 alcoholic drinks 3 days/week Glycemic Parameters A1C: 8.5% FPG: 11.8 mmol/l Medications Gliclazide modified release (90 mg QD) Sitagliptin and metformin HCL-extended release (100 mg sitagliptin/2000 mg metformin QD) Rosuvastatin (10 mg QD) Ramipril (10 mg QD) Notes Health Status BMI: 29.4 kg/m 2 BP: 138/88 mmhg egfr: 68 ml/min/1.73m 2 ACR: Negative LDL: 1.9 mmol/l CV: No history of cardiovascular disease, but strong family history Exercise: On her feet during the day at work Diet: Indian vegetarian diet; does not drink alcohol Glycemic Parameters A1C: 8.3% FPG: 8.5 mmol/l Medications Metformin 1000 mg BID Sitagliptin 100 mg QD Empagliflozin 10 mg QD Atorvastatin 10 mg QD Amlodipine 5 mg QD Was previously on gliclazide but stopped due to daytime hypoglycemia Insulin Treatment Regimen Basal: Insulin glargine U units at bedtime 2
28 Initiating Basal Insulin in Type 2 Diabetes Start: 10 units once daily Titration: 1 unit per day until target reached (detemir, glargine and NPH) Degludec should be titrated by 2 units every 3 4 days or by 4 units once a week Switching Basal Insulin in T2DM From once-daily basal 2,3,4,5 1:1 From BID basal 2,3,4,5 20% From IGlar U300 2,3 20% Followed by daily or weekly titration (as described above) Basal Insulin Product Options and Features Insulin type Brand name Total units per pen (units) Maximum single dose for injection (units) In-use time (days) Pre-filled pen Insulin degludec Insulin detemir Tresiba 100 units/ml Tresiba 200 units/ml Levemir 100 units/ml Lantus 100 units/ml FlexTouch FlexTouch FlexTouch * SoloSTAR * Insulin glargine NPH Basaglar 100 units/ml Toujeo 300 units/ml Novolin ge NPH 100 units/ml Kwikpen * SoloSTAR Cartridge only Humulin N 100 units/ml Kwikpen * * Also available in cartridges for use in durable/refillable pens; max dose in durable pen may differ from max dose in prefilled pens above. 3
29 Enhancing Conversations Guide Use the following guide to help enhance your conversations with patients with type 2 diabetes who are taking basal insulin. Current glycemic control Questions What targets did we set for you? Fasting blood glucose (FPG)? Glycated hemoglobin (A1C)? Review blood glucose journal: How many of your morning FPG readings are at target? Does your FPG vary from day to day? Considerations What factors may contribute to: An above-target FPG (e.g., hypoglycemia, suboptimal insulin dose)? Day-to-day variability (e.g., changing schedule, insulin type) Administration Questions What time(s) do you typically inject basal insulin? In a typical week, how often do you miss the regular dosing time for your basal insulin? Show me how and where you normally inject your basal insulin each day Considerations If the patient takes basal insulin BID, consider switching to a longer-acting basal insulin If the patient is taking a high dose, consider a: More concentrated insulin for a smaller injection volume Pen with a different maximum dose Discuss how to manage missed/delayed doses for the patient s basal insulin Consider a basal insulin that affords some flexibility in the timing of administration and/or can be administered in the morning or at bedtime Regarding injection technique: Based on the type and features of the pen device (e.g., prefilled vs. refillable, ease of injecting), is a switch appropriate? Looking at the type and features of the pen needle (e.g., size, gauge), is a switch appropriate? Remind the patient that pen needles are designed for single-use only Reinforce injection-site rotation Assessing for low blood sugar Questions How often has your blood sugar dropped below 4 mmol/l in the last 3 months? How often have you experienced symptoms? (e.g., headaches, dizziness) When do they happen? (e.g., during the day, at bedtime, in the night) Are you snacking to prevent or treat low blood sugar? Have episodes of low blood sugar caused you to change your insulin regimen? Considerations Investigate possible causes of the hypoglycemia (e.g., alcohol consumption, chronic kidney disease, recent weight loss) Discuss ways to reduce the risk of hypoglycemia, such as: Reducing the basal/bolus insulin dose (depending on the timing of the hypoglycemic episode in comparison to time/action profile of injected insulin) Switching the patient to a basal insulin with a lower risk of hypoglycemia Reducing dose of concurrent sulfonylurea therapy For additional support, refer the patient to a diabetes educator If the patient experiences hypoglycemia unawareness, refer to an endocrinologist Optimizing control Questions What is your current dose of basal insulin? Are you still adjusting your insulin dose? If yes, what is your titration schedule? If no, why not? Considerations If the patient is not at their FPG target and not experiencing nocturnal, severe or frequent mild episodes of hypoglycemia, optimize the dose of basal insulin Discuss example dosage adjustment schedules, and remind the patient that insulin has no dose ceiling 4
30 Key Takeaways Goal of insulin treatment: Get to A1C target with as few adverse events as possible. Enhance conversations with your patients Consider CGM and FGM to reduce A1C and hypoglycemia Nocturnal and symptomatic hypoglycemia: Use basal insulin analogues over NPH Overall and nocturnal hypoglycemia: Use insulin glargine U300 or insulin degludec over insulin glargine U100 Patients at high CV risk: Use insulin degludec over insulin glargine U100 to reduce risk of hypoglycemia Low glucose variability is associated with a lower rate of severe hypoglycemia, MACE and all-cause mortality compared to medium or high variability CGM: continuous glucose monitoring; FGM: flash glucose monitoring; MACE: major adverse cardiovascular event REFERENCES 1. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S Sanofi-aventis Canada Inc. Lantus Product Monograph Eli Lilly Canada Inc. BASAGLARTM Product Monograph Sanofi-aventis Canada Inc. Toujeo TM Product Monograph Novo Nordisk Canada Inc. Tresiba Product Monograph Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(S2):S2-3-S Ish-Shalom M, Wainstein J, Raz I, Mosenzon O. Improvement in Glucose Control in Difficult-to-Control Patients With Diabetes Using a Novel Flash Glucose Monitoring Device. J Diabetes Sci Technol. 2016;10(6):
31 Notes 6
32 Basal Insulin Dosing Guide Starting basal insulin for type 2 diabetes 1 With the help of your healthcare provider, fill out the form below to get started with your basal insulin treatment. Basal insulin prescribed: Starting dose: units, time(s) per day, taken Basal insulin should be adjusted until the pre-breakfast (fasting) blood sugar target is reached. Adjusting your basal insulin dose 1. Take your pre-breakfast (fasting) blood sugar measurement 2. Check where your blood sugar is on the chart below to see what to do Morning blood sugar measurement (mmol/l) Target range BELOW TARGET Reduce dose UNITS ON TARGET Dose remains the same ABOVE TARGET Increase dose + UNITS Check the days of the week you will adjust your insulin dose: Monday Tuesday Wednesday Thursday Friday Saturday Sunday Missed dose If a dose of insulin glargine is missed or if not enough has been injected, your blood sugar level may become too high (hyperglycemia). Do not take a double dose to make up for a forgotten dose. 2,3 If a dose of insulin degludec is missed, the missed dose should be taken as soon as you remember, making sure there are at least 8 hours between doses. Following that, continue with your regular dosing schedule. 4
33 Sick-day management Illness, especially with nausea and vomiting, diarrhea and/or fever, may change how much basal insulin you need. Even if you are not eating, you will still require insulin. You and your healthcare professional should establish a sick-day plan for you to use in case of illness. When you are sick, test your blood/urine frequently and call your healthcare professional as instructed. 2 Sick-day plan: What you need to know about hypoglycemia (low blood sugar) Treatment of diabetes with insulin can sometimes lead to hypoglycemia. Symptoms of hypoglycemia can include feeling shaky, light-headed, nauseated, nervous, anxious, hungry, confused, sweaty and weak. Measuring your blood sugar regularly will tell you if your blood sugar is too high or too low. When your blood sugar falls below your target range (for most people, this is usually about 4 mmol/l), this is called hypoglycemia. Hypoglycemia can happen quickly, so it is important to treat it right away. If your blood sugar drops very low, you may lose consciousness and need help from another person. 5 What should you do if you think you are experiencing hypoglycemia? Diabetes Canada suggests treating mild-to-moderate hypoglycemia with 15 g of fast-acting carbohydrate. For example 5 : 15 g of glucose in the form of glucose tablets 15 ml (1 tablespoon) or 3 packets of sugar dissolved in water 150 ml (2/3 cup) of juice or regular pop 6 Life Savers (1 = 2.5 g of carbohydrate) 15 ml (1 tablespoon) of honey (do not use for children less than 1 year old) Wait 15 minutes, then check your blood sugar again. If it is still below 4 mmol/l: Treat again; wait 15 minutes, check your blood sugar. Continue these steps until your blood sugar is above 4 mmol/l When your blood sugar is above 4 mmol/l: If your next meal is more than 1 hour away, or you are going to be active, eat a snack with 15 g of carbohydrate and a protein source (e.g., half a sandwich or cheese and crackers) Do not drive for 40 minutes DO NOT TAKE ANY INSULIN IF YOU ARE EXPERIENCING OR THINK YOU MAY BE EXPERIENCING HYPOGLYCEMIA. References: 1. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42:S1-S sanofi-aventis Canada Inc. Lantus Product Monograph sanofi-aventis Canada Inc. Toujeo SoloSTAR Product Monograph Novo Nordisk Canada Inc. Tresiba Product Monograph Diabetes Canada. Lows and highs: blood glucose levels Available at: Retrieved May 17, 2018.
Starting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationLET S TALK INSULIN THE BASICS
LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationWhat do you need to know before you go home?
What do you need to know before you go home? What is Insulin Types of Insulin Injection Sites How to Inject Insulin Correctly Low Blood Sugar and Treatment Sick Day Management After leaving the Hospital:
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationGET TO TARGET Considerations for adding long-acting GLP-1 RAs
GET TO TARGET Considerations for adding long-acting GLP-1 RAs GLP-1 RAs, glucagon-like peptide-1 receptor agonists Faculty/presenter disclosure Faculty: Sorin Beca Relationships with financial sponsors:
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationWhat s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy
What s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy 2013 Rocky Mountain/ACP Internal Medicine Conference November 15, 2013 David C.W. Lau, MD, PhD,
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationThe Signs, Symptoms, and Causes of Hypoglycemia
The Signs, Symptoms, and Causes of Hypoglycemia Tam Doan PharmD, CDE, BC-ADM Clinical Pharmacist, Diabetes Care Manager Santa Clara Valley Medical Center Fruitdale, CA Agenda What is hypoglycemia? What
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationDiabetes: What You Need to Know
UW MEDICINE PATIENT EDUCATION Diabetes: What You Need to Know Discharge review before you leave the hospital We want to be sure that we explained your diabetes instructions well, so that you know how to
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationComplete this CE activity online at ProCE.com/InsulinPart2
Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over
More informationHypoglycemia, Sick Days/DKA and Hospitalization
Hypoglycemia, Sick Days/DKA and Hospitalization General survival skills for your client with diabetes at home and in Hospital Diabetes Canada guidelines for your client with diabetes while they are in
More informationGoing home with Diabetes from the Emergency Department
Going home with Diabetes from the Emergency Department When should I see my health care provider or go to an Emergency Department? You may need to see your health care provider or go to the Emergency Department
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationGuide to Starting and Adjusting Insulin for Type 2 Diabetes*
Guide to Starting and Adjusting Insulin for Type 2 Diabetes* www.cadth.ca * Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes, 2008 International Diabetes Center, Minneapolis, MN.
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationORAL AGENT FAILURE AND GLP1 FAILURE TO REACH GOALS WHERE DO WE GO FROM HERE
ORAL AGENT FAILURE AND GLP1 FAILURE TO REACH GOALS WHERE DO WE GO FROM HERE key objectivies UNDERSTAND HOW TO DEFINE ORAL and INGECTABLE AGENT FAILURES understand benefit of QUADRUPLE oral agents vs
More informationCase study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease
Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationLearning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications
Treatment Strategies to Maximize the Value of Diabetes Medications Presenters: Jennifer Toy, PharmD, BCACP and Crystal Zhou, PharmD, APh AHSCP, BCACP Learning Objectives 1. Discuss which patients may benefit
More informationCASES DR TINA KADER MCGILL JGH; LMC CVPH CDE
CASES DR TINA KADER MCGILL JGH; LMC CVPH CDE Faculty/Presenter Disclosure Faculty/Presenter: tina kader Relationships with commercial interests: Grants/research support: BI; Sanofi Speaker s bureau/honoraria:
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationI have no financial incentives or conflicts of interest to disclose for this presentation.
Jacob Lenzmeier, PharmD Resident Pharmacist-CentraCare Health November 9, 2017 1 I have no financial incentives or conflicts of interest to disclose for this presentation. 2 1 Review the mechanism of action,
More informationThis case study is supported by an educational grant from Abbott.
Program Name: Planning Committee: When and How to Start or Intensify Insulin Therapy in Your Patients with Type 2 Diabetes Alice Cheng, MD, FRCPC Jean-Francois Yale, MD, CSPQ Lori Berard, RN, CDE Sol Stern,
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationLantus to levemir conversion
Lantus to levemir conversion The Borg System is 100 % Lantus to levemir conversion 16-6-2005 Ask the Expert on... Lantus Conversion. Karen Shapiro, PharmD, BCPS. Disclosures. June 16, 2005. Question. Would
More informationAll Things Insulin: Dosing, Monitoring, Titrating, Transitioning
All Things Insulin: Dosing, Monitoring, Titrating, Transitioning Target Audience: Pharmacists ACPE#: 0202-0000-18-052-L01-P Activity Type: Application-based Disclosures Stuart Haines declares that he has
More informationBlood Sugar and Insulin
PATIENT & CAREGIVER EDUCATION Blood Sugar and Insulin This information explains high and low blood sugar levels and how to manage them. About Blood Sugar and Insulin Your body uses a sugar called glucose
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationModule 5. Understanding Insulin Therapy
Module 5. Understanding Insulin Therapy EDUCATIONAL OBJECTIVES Upon completion of this activity, participants will be better able to: 1. Define the basic physiologic concept of basal-bolus insulin; 2.
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationInitiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital
Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More information5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:
Insulin Workshop Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Holly Divine, PharmD, BCACP, BCGP, CDE,
More informationManagement: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018
Management: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018 Disclosures I have no Objectives Use a case-based format to discuss diabetes management pearls Discuss
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationLOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA
LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA Anne Leake, PhD, APRN-Rx, BC-ADM ECHO Diabetes Learning Group 3/28/2018 Objectives 1. Identify common preventable causes of hypoglycemia
More informationLantus levemir conversion
Lantus levemir conversion Search Learn about starting insulin-naïve patients with type 2 diabetes on Levemir. Read Important Safety & Prescribing Info on the HCP Website. Lantus and Levemir have a variety
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationManaging Diabetes when you are having a colonoscopy
Managing Diabetes when you are having a colonoscopy Disclaimer This is general information developed by The Ottawa Hospital. It is not intended to replace the advice of a qualified health-care provider.
More informationUNIT FOUR LESSON 10 OUTLINE
UNIT FOUR LESSON 10 OUTLINE Welcome participants to the final unit in the series Taking Ownership of Your Diabetes Ask participants how they are doing in terms of the Diabetes Checklist and goal setting.
More informationA GUIDE TO STARTING HUMALOG
A GUIDE TO STARTING HUMALOG This booklet is intended only for those who have been prescribed Humalog. It is intended to be used in addition to the Patient Information Leaflet (PIL) which is included in
More informationProduct Theaters. Light refreshments provided by the American Diabetes Association will be served to the first 300 attendees.
Product Theaters Product Theaters, located in the rear of the Exhibit Hall, offer informative sessions focusing on particular products or a single facet of diabetes. Product Theater sessions do not provide
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationDiabetes Management in New Brunswick Nursing Homes
Diabetes Management in New Brunswick Nursing Homes Prepared by Dr. Angela McGibbon March, 2016 As the population ages and with the rising incidence of diabetes, there are increasing numbers of people with
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationInsulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination. Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM
Insulin Bootcamp: Dosing, Monitoring, Titrating, and Care Coordination Stuart T. Haines, Pharm.D., BCPS, BCACP, BC ADM University of Mississippi School of Pharmacy Joshua J. Neumiller, Pharm.D., CDE, FAADE,
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationEndocrinology and Diabetes. Steroid-Induced Diabetes Education Handbook
Endocrinology and Diabetes Steroid-Induced Diabetes Education Handbook High blood sugar (Hyperglycemia) Causes High blood sugar (also called hyperglycemia) is when there is too much sugar in your
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More information8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy
Insulin Basics Anabolic hormone involved in metabolism Following carbohydrate ingestion insulin release is stimulated Suppresses hepatic glucose production Stimulates peripheral glucose uptake Commercially-available
More informationDiabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services
Diabetes Meds Update 2016 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Disclaimer and Important Info This content is for educational purposes only. Please see Package
More informationEmerging Challenges in Primary Care: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins
Emerging Challenges in Primary Care: 2018 Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins 1 Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationSample Exam Questions
Disclaimer These are not validated questions. They have been created to enhance your learning and provide practice in reading and answering multiple choice questions. Some questions have been created to
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationGLUCAGON ADMINISTRATION STUDENTS WITH TYPE 1 DIABETES DECEMBER
GLUCAGON ADMINISTRATION STUDENTS WITH TYPE 1 DIABETES DECEMBER 6 2013 PURPOSE To train designated school staff how to recognize low blood sugar and administer glucagon for treatment of severe low blood
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationAdvanced Pharmacology Diabetes Homework
Advanced Pharmacology Diabetes Homework Points: 25 Comments: Name: Tracy Hill WU ID #: 20015608 E-mail: tracy.hill@washburn.edu _TH I hereby certify that the work submitted is my own, and that I have not
More informationEvidence and Guidelines TECHNOLOGY 2016 Tina Kader, MD
Evidence and Guidelines TECHNOLOGY 216 Tina Kader, MD Staff endocrinologist Jewish General Hospital Certified Diabetes Educator Montreal, Quebec AACE/ACE 215 Guidelines Glucose Monitoring: When, How, and
More informationHypoglyceamia and Exercise
Hypoglyceamia and Exercise Noreen Barker Diabetes Specialist Nurse May 2016 Hypoglyceamia What is a hypo? Why are we concerned? Signs and symptoms Treatments Causes Hypo unawareness Managing diabetes and
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationDiabetes education material. 1. Fasting plasma glucose (FPG) (No caloric intake for at least 8 hours)
How do I assess plasma glucose control? Diabetes education material There are four different ways to assess plasma glucose control: 1. Fasting plasma glucose (FPG) (No caloric intake for at least 8 hours)
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationNext Generation Diabetes Management:
Next Generation Diabetes Management: Titratable Fixed-Ratio Combination Therapy with Basal Insulin/GLP-1 RA to Better Manage Type 2 Diabetes Supported by an educational grant from Sanofi US Learning Objectives
More informationSanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018
Sanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018 Background: For people with diabetes the early months of treatment with long-acting insulin are important for
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More information